About Biosyntech
Biosyntech is a Healthcare company based in Laval (Canada) founded in 1994, and was acquired by Piramal Group in June 2010. It operates as a biotherapeutic thermogels are developed for tissue repair applications. Biosyntech has raised $1.4 million across 1 funding round from investors including Piramal Group, ProQuest Investments and Highland Capital Partners. Its focus areas include Life Sciences, Wound Care, Drugs and Regenerative Medicine. Its competitors include Augmenix, AmacaThera, QBiotics, MediWound and Ilya Pharma and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
BioSyntech was founded in 1994 in Laval, Canada, as a biotechnology firm. Chitosan-based hydrogels, known as BST-Gel, were developed for cartilage repair and therapeutic agent delivery. These thermogels, liquid at low temperatures and solid at body temperature, were designed for injection or application to sites like damaged cartilage, bone, and chronic wounds. Bankruptcy was filed in May 2010, followed by acquisition by Piramal Healthcare in June 2010.
- Headquarters Laval, Canada
- SectorsHealthcare
- Website biosyntech.com
- Social LinkedIn
- Acquired by Piramal Group (Jun 2010)
- Total Equity Funding$1.4M (USD)
in 1 rounds
- Latest Funding Round$1.4M (USD), Series A
Jun 2009
- InvestorsPiramal Group
& 4 more
- Acquired byPiramal Group
(Jun 2010)
Funding Insights of Biosyntech
Biosyntech has successfully raised a total of $1.4M through 1 strategic funding round. The most recent funding activity was a Series A round of $1.4 million completed in June 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.4M
- Total Rounds 1
- Last Round Series A — $1.4M
- First Round $1.4M
(Jun 2009)
- Investors Count 4
All 1 funding rounds of Biosyntech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2009 | $1.4M | Series A | – | – |
5 investors in total: 5 institutional.
Investors in Biosyntech
Biosyntech has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Piramal Group, ProQuest Investments and Highland Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | proquestvc.com | - | |
Venture capital investment and entrepreneur support services. | – | hcp.com | - | |
VC firm focusing on life science sector | – | pappas-capital.com | Durham, United States | |
Offers savings plans, investments, and financing for businesses and individuals. | 1983 | fondsftq.com | Montreal, Canada | |
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | 1984 | piramal.com | Mumbai, India |
Investor details for Biosyntech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Biosyntech
3 dated milestones of Biosyntech across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Biosyntech is founded.
- Funding First funding round of $1.4M.
- Exit Acquired by Piramal Group.
Competitors of Biosyntech
Biosyntech has 10 listed competitors in our database, 10 of them funded. They include Augmenix, AmacaThera, QBiotics, MediWound and Ilya Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| augmenix.com | 2008 | Waltham, United States | $46.6M | 153 | Hydrogel spacers are provided for prostate cancer radiation therapy. | |
| amacathera.ca | 2015 | Toronto, Canada | $14.22M | – | Injectable hydrogel platform developed for therapeutic medical applications. | |
| qbiotics.com | 2000 | Brisbane, Australia | $98.07M | – | Small molecules from plant extracts are developed for medical applications. | |
| mediwound.com | 2001 | Yavne, Israel | $18M | – | Enzymatic therapies for tissue repair and regeneration are developed. | |
| ilyapharma.se | 2016 | Uppsala, Sweden | $4.02M | – | Biological drugs for skin and mucosa wound treatment are developed. | |
| resolution-tx.com | 2017 | Edinburgh, United Kingdom | $119.88M | 6 | Macrophage cell therapies are developed for inflammatory and liver diseases. | |
| profibrix.com | 2004 | Leiden, Netherlands | $33M | – | Powdered fibrin sealant for surgical bleeding | |
| clarisbio.com | 2018 | Jersey, United States | $44.5M | – | Topical formulations for corneal wounds, ulcers, and scars are developed. | |
| tempothera.com | 2014 | San Diego, United States | $20.17M | – | Regenerative biomaterials for wounds are developed using particle technology. | |
| solsysmedical.com | 1999 | Norfolk, United States | $37.24M | – | Human skin allografts and dressings for wound care are supplied. |
Detailed competitors of Biosyntech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Wound Care
10 companies that operate in the same segment as Biosyntech (Wound Care), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Fish-skin acellular dermal matrix technology is provided for wound treatments. | 2007 | Isafjordur, Iceland | USD 93.11 M | – | 150 | |
Developer of advanced haemostat and wound care dressing products | 2008 | Ahmedabad, Gujarat, India | USD 42.71 M | USD 2.88 M | 70 | |
Oxygen-based wound therapy devices are developed for healing non-healing wounds. | 2003 | Waterbeach, Cambridgeshire, United Kingdom | USD 68.39 M | – | – | |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | – | USD 418.63 M | 837 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M | – | – | |
Regenerative therapies for wound care are developed and commercialized. | 1985 | Canton, Ohio, United States | USD 30 M | USD 564.17 M | 869 | |
Cold plasma solutions for wound treatment are developed. | 2013 | Eindhoven, Noord-brabant, Netherlands | USD 7.06 M | – | – | |
Point-of-care devices for wound bacterial assessment are provided. | 2013 | Toronto, Ontario, Canada | USD 43.2 M | – | 49 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biosyntech
Biosyntech was founded in 1994 and raised its 1st funding round 15 years after it was founded.
Biosyntech is headquartered in Laval, Canada. It is registered at Laval, Quebec, Canada.
Biosyntech is a funded company, having raised a total of $1.4M across 1 funding round to date. The company's 1st funding round was a Series A of $1.4M, raised on Jun 2009.
BioSyntech was founded in 1994 in Laval, Canada, as a biotechnology firm. Chitosan-based hydrogels, known as BST-Gel, were developed for cartilage repair and therapeutic agent delivery. These thermogels, liquid at low temperatures and solid at body temperature, were designed for injection or application to sites like damaged cartilage, bone, and chronic wounds. Bankruptcy was filed in May 2010, followed by acquisition by Piramal Healthcare in June 2010.
Biosyntech's top competitors include Ilya Pharma, AmacaThera and Augmenix.
Biosyntech has 5 investors. Key investors include Piramal Group, ProQuest Investments, Highland Capital Partners, Fonds de solidarite FTQ, and Pappas Capital.
Yes. Biosyntech was acquired by Piramal Group in June 2010.